Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Rigel Pharmaceuticals announced that VEPPANU (vepdegestrant), the first and only FDA-approved PROTAC, is now available by prescription in the U.S. for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer. The drug is priced at $29,400 per 30-day supply and is immediately available through specialty distributors and pharmacies, with patient support programs offered via RIGEL ONECARE.
Key figures
- Drug Name
- VEPPANU (vepdegestrant)
- Dosage
- 200 mg orally once daily
- Price per 30 days
- $29,400
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.